Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

FDA takes aim at pharma’s biosimilar-delaying tactics

Ever-rising cost of insulins also to be targeted

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

- PMLiVE

NHS says Humira biosimilar deal will save £300m

AbbVie also submitted a bid into tender process

Roche Basel Switzerland

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

Roche Basel Switzerland

Roche and AbbVie prepare to move Venclexta into first-line CLL

Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

Roche Basel Switzerland

Roche preps new Kadcyla filings after phase 3 trial win

Says the drug significantly reduced IDFS in women with residual disease

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links